ArticleJournal of inflammation research2023
The Diagnostic Value of Inflammatory Markers (CRP, IL6, CRP/IL6, CRP/L, LCR) for Assessing the Severity of COVID-19 Symptoms Based on the MEWS and Predicting the Risk of Mortality.
Article in Journal of inflammation research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- The Effect of Potassium Canrenoate (Mineralocorticoid Receptor Antagonist) on the Markers of Inflammation in the Treatment of COVID-19 Pneumonia and Fibrosis-A Secondary Analysis of Randomized Placebo-Controlled Clinical Trial.International journal of molecular sciences · 2023Trial
- Heterogeneity of Immunological, Coagulation and Complement Clustering to Viral Challenge and Clinical Relevance.International journal of molecular sciences · 2026Article
- The Association Between Peak IL-6 Levels, In-Hospital Mortality, and Selected Risk Factors in Patients Hospitalized for COVID-19 at the Temporary Hospital in Gdansk-A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Exosomal lncRNA DLEU2 aggravates inflammatory injury and apoptosis in pediatric viral pneumonia via the miR-330-5p.Hereditas · 2026Article
- Hematological and biochemical markers for predicting severity in COVID-19 patients.BMC infectious diseases · 2026Observational
- Developing a prediction model for poor prognosis in MPA patients using initial admission examination results: a machine learning study from Southwest China.Frontiers in immunology · 2026Article
- Chemokines as potential biomarkers for predicting the course of COVID-19 - a review of the literature.Frontiers in immunology · 2025Review
- Back to Basics: The Diagnostic Value of a Complete Blood Count in the Clinical Management of COVID-19.Diagnostics (Basel, Switzerland) · 2024Article
- Lung Ultrasound Efficacy in Monitoring Post-SARS-CoV-2 Pneumonia and Inflammatory Biomarkers in Pediatric Patients.Medicina (Kaunas, Lithuania) · 2024Observational
- Article
- The Onset of Antinuclear Antibodies (ANAs) as a Potential Risk Factor for Mortality and Morbidity in COVID-19 Patients: A Single-Center Retrospective Study.Biomedicines · 2024Article
- Significance of nitrosative stress and glycoxidation products in the diagnosis of COVID-19.Scientific reports · 2024Article
- Assessing the Diagnostic Values of the Neutrophil-to-Lymphocyte Ratio (NLR) and Systematic Immunoinflammatory Index (SII) as Biomarkers in Predicting COVID-19 Severity: A Multicentre Comparative Study.Medicina (Kaunas, Lithuania) · 2024Article
- Prediction of the risk of mortality in older patients with coronavirus disease 2019 using blood markers and machine learning.Frontiers in immunology · 2024Article
- Factors Associated with Mortality Among Severe Omicron Patients for COVID-19.Infection and drug resistance · 2024Article
- Redox Biomarkers - An Effective Tool for Diagnosing COVID-19 Patients and Convalescents.Journal of inflammation research · 2024Article
- Unveiling COVID-19 Secrets: Harnessing Cytokines as Powerful Biomarkers for Diagnosis and Predicting Severity.Journal of inflammation research · 2023Article
- Changes in chemokine and growth factor levels may be useful biomarkers for monitoring disease severity in COVID-19 patients; a pilot study.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Various diagnostic tools are used to assess the severity of COVID-19 symptoms and the risk of mortality, including laboratory tests and scoring indices such as the Modified Early Warning Score (MEWS). The diagnostic value of inflammatory markers for assessing patients with different severity of COVID-19 symptoms according to the MEWS was evaluated in this study. Materials and Methods: The concentrations of CRP (C-reactive protein) (immunoassay) and IL6 (interleukin 6) (electrochemiluminescence assay) were determined, and CRP/IL6, CRP/L, and LCR ratios were calculated in blood serum samples collected from 374 COVID-19 patients. Results: We demonstrated that CRP, IL6, CRP/IL6, CRP/L, LCR inflammatory markers increase significantly with disease progression assessed based on the MEWS in COVID-19 patients and may be used to differentiating patients with severe and non-severe COVID-19 and to assess the mortality. Conclusion: The diagnostic value of inflammatory markers for assessing the risk of mortality and differentiating between patients with mild and severe COVID-19 was confirmed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.